NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
Clinical Trials
17 trialsNCT01239108 2024-08-02
Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Astex Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT05209308 2023-03-16
CORAL
MEI Pharma, Inc.
Phase 2 Withdrawn
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT00551239 2020-10-19
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
CTI BioPharma
Phase 3 Withdrawn
NCT02786485 2020-10-05
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT02973191 2017-04-10
ORBIT
Celgene
Phase 1/2 Withdrawn
NCT02215629 2017-01-27
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
Verastem, Inc.
Phase 1 Withdrawn
NCT02640833 2016-07-26
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
AbbVie
Phase 1 Withdrawn
NCT02556346 2016-03-02
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Molecular Templates, Inc.
Phase 1 Withdrawn
NCT01739491 2015-12-02
A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia
Janssen Pharmaceutica
Withdrawn
NCT00081055 2014-12-04
OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies
Mesoblast, Ltd.
Phase 2 Withdrawn
NCT01326078 2014-03-26
Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures.
CristĂĄlia Produtos QuĂmicos FarmacĂȘuticos Ltda.
Phase 2/3 Withdrawn
NCT01478074 2014-01-03
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Altor BioScience
Phase 1 Withdrawn
NCT00129558 2013-12-04
A Study to Evaluate PT-523 in Patients With Refractory Leukemia
Spectrum Pharmaceuticals, Inc
Phase 1/2 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT00485966 2008-11-05
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Cylene Pharmaceuticals
Phase 2 Withdrawn